Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

entecavir

- PMLiVE

Watson completes Actavis acquisition, will rebrand in 2013

Will bring its global operations under the Actavis name from next year

Bristol-Myers Squibb (BMS) building

BMS cuts salesforce on revised Abilify deal

Nearly 500 jobs to go as US rights to schizophrenia blockbuster return to Otsuka

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

GSK sales drop as austerity measures hit business in Europe

Revenues in region drop 9 per cent

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

- PMLiVE

Sanofi nearing end of patent cliff, says Viehbacher

Higher third-quarter revenues see pharma company raise forecasts for 2012

- PMLiVE

New CEO says AZ open to acquisitions to rebuild pipeline

Comments come as Q3 operating profit plummets 47 per cent

Bristol-Myers Squibb (BMS) building

BMS slides to loss as Plavix revenues dry up

Records net loss of $711m during third quarter

UK flag

UK could allow patented drugs to be used in clinical trials

Government proposes update to Patents Act to restrict when companies can sue for infringement

Europe set to approve first Glivec generic

CHMP backs Teva version of Novartis' blockbuster cancer drug

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links